Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breviscapine on Viable Myocardium and LV Remodeling After CTO Revascularization
ChiCTR-IPC-16010161Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis and Chronic total occlusion of the coronary artery (CTO) comparing Breviscapine with Placebo (2 arms). Primary endpoint: Change in viable myocardium at 12 months. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
Dengzhanxixin
03
Conditions
coronary arteriosclerosisChronic total occlusion of the coronary artery (CTO)
Beyond the preview
Go deeper on ChiCTR-IPC-16010161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-16010161.